The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 25, 2015
Filed:
Oct. 04, 2011
Ichiro Watanabe, Tokyo, JP;
Yoshiharu Hiruma, Tokyo, JP;
Eisuke Tsuda, Tokyo, JP;
Tatsuji Matsuoka, Tokyo, JP;
Toshiaki Ohtsuka, Tokyo, JP;
Tohru Takahashi, Tokyo, JP;
Toshinori Agatsuma, Tokyo, JP;
Sandra Miller, Munich, DE;
Robert Mühlbacher, Martinsried/Planegg, DE;
Kathrin-ladetzki Baehs, Martinsried/Planegg, DE;
Steffen Runz, Martinsried/Planegg, DE;
Ulrike Schubert, Munich, DE;
Ingrid Schuster, Munich, DE;
Dirk Ponsel, Germering, DE;
Ichiro Watanabe, Tokyo, JP;
Yoshiharu Hiruma, Tokyo, JP;
Eisuke Tsuda, Tokyo, JP;
Tatsuji Matsuoka, Tokyo, JP;
Toshiaki Ohtsuka, Tokyo, JP;
Tohru Takahashi, Tokyo, JP;
Toshinori Agatsuma, Tokyo, JP;
Sandra Miller, Munich, DE;
Robert Mühlbacher, Martinsried/Planegg, DE;
Kathrin-Ladetzki Baehs, Martinsried/Planegg, DE;
Steffen Runz, Martinsried/Planegg, DE;
Ulrike Schubert, Munich, DE;
Ingrid Schuster, Munich, DE;
Dirk Ponsel, Germering, DE;
Daiichi Sankyo Company, Limited, Tokyo, JP;
Abstract
An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.